文献速递肾小球疾病慢性肾脏病

狼疮性肾炎慢性化评分对结局的预测价值评估

Evaluating Chronicity Scores for Outcomes in Patients With Lupus Nephritis.
PubMed 文献 · Kidney Int Rep · 2026-01-13

本研究为回顾性队列研究,纳入307例活检证实的狼疮性肾炎患者,比较Mayo Clinic慢性化评分(MCCS)与NIH慢性化指数(NIH-CI)的预后价值。结果显示两者预测蛋白尿缓解、完全肾脏缓解和终末期肾病的效能相当,且独立预测肾脏结局的成分均为间质纤维化/肾小管萎缩。

要点

  • MCCS与NIH-CI对狼疮性肾炎肾脏结局的预测效能相当。
  • 间质纤维化/肾小管萎缩是唯一独立预测肾脏结局的慢性化成分。
  • 两评分在非增殖性狼疮性肾炎和基线肾功能减退患者中均适用。

核心结论

  • MCCS与NIH-CI在狼疮性肾炎中提供相当且附加的预后信息。
  • MCCS所捕获的慢性病变与肾脏结局最强相关,其中IF/TA是预后的主要决定因素。

研究设计与样本

  • 回顾性队列研究,纳入307例活检证实的狼疮性肾炎患者,1992-2023年在Mayo Clinic评估。
  • 使用NIH-CI和MCCS对慢性组织学损伤进行分级,采用性别分层、年龄校正的Cox模型。

主要发现

  • 较高的NIH-CI和MCCS评分与较低的PR500和CRR可能性相关(HR均为0.75)。
  • 较高的NIH-CI和MCCS评分与较高的ESKD风险相关(HR分别为1.40和1.33)。
  • 将任一评分加入临床模型可改善对PR500(C指数0.65至0.71)、CRR(0.64至0.71)和ESKD(0.81至0.85)的区分度,但对死亡率无改善(ΔC=0.00)。
  • 决策曲线分析显示NIH-CI和MCCS的净获益相似。
  • IF/TA是唯一独立预测肾脏结局的成分。

关键数值与推荐

  • PR500定义为蛋白尿缓解<500 mg/d。
  • CRR为完全肾脏缓解,ESKD为终末期肾病,死亡为全因死亡。
  • 亚组分析按基线eGFR(<60 vs. ≥60 ml/min per 1.73 m2)和病理分型(增殖性 vs. 非增殖性)进行。

临床怎么用

  • MCCS和NIH-CI均可用于狼疮性肾炎的预后评估,尤其关注IF/TA。
  • 在非增殖性狼疮性肾炎和基线肾功能减退患者中也可应用两评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of this study was to evaluate the prognostic value of the Mayo Clinic Chronicity Score (MCCS) compared with the National Institutes of Health (NIH) Chronicity Index (NIH-CI) in lupus nephritis (LN). METHODS: We conducted a retrospective cohort study of 307 patients with biopsy-proven LN evaluated at Mayo Clinic (1992-2023). Chronic histologic injury was graded using the NIH-CI and MCCS. Outcomes were proteinuria remission < 500 mg/d (PR500), complete renal response (CRR), end-stage kidney disease (ESKD), and all-cause mortality. Sex-stratified, age-adjusted Cox models were used. Prognostic performance was evaluated using change in Harrell's C-index (ΔC over a clinical model) and decision-curve analysis was used to assess clinical utility for 5-year ESKD. Subgroup analyses were used to test for effect modification by baseline estimated glomerular filtration rate (eGFR) (< 60 vs. ≥ 60 ml/min per 1.73 m2) and histologic class (proliferative vs. nonproliferative). RESULTS: Higher NIH-CI and MCCS scores were associated with lower likelihood of PR500 and CRR (hazard ratio [HR]: 0.75 for both) and greater risk of ESKD (HR: 1.40 for NIH-CI; 1.33 for MCCS). Adding either score to a clinical model improved discrimination for PR500 (C-index: 0.65 to 0.71), CRR (0.64 to 0.71), and ESKD (0.81 to 0.85), but not mortality (ΔC = 0.00). Decision-curve analysis showed similar net benefits for NIH-CI and MCCS. Interstitial fibrosis (IF) and tubular atrophy (TA) (IF/TA) were the only components independently predictive of renal outcomes. Our findings support applicability of both scores in nonproliferative LN and in patients with reduced baseline kidney function. CONCLUSION: The MCCS and NIH-CI provide comparable and additive prognostic information in LN. MCCS captured the chronic lesions most strongly associated with renal outcomes, with IF/TA as the principal determinant of prognosis.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Cuéllar-Gutiérrez MC, Navarro-Mendoza E, Flores-Gouyonnet J, et al. Evaluating Chronicity Scores for Outcomes in Patients With Lupus Nephritis. Kidney Int Rep. 2026. PMID: 41716734. doi:10.1016/j.ekir.2026.103778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。